Revvity (NYSE:RVTY) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Revvity (NYSE:RVTY) posted its quarterly earnings data on Tuesday. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08, Zacks reports. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. During the same quarter last year, the company posted $1.18 earnings per share. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year.

Here are the key takeaways from Revvity’s conference call:

• Revvity exceeded expectations in Q3, delivering 7% pro forma organic growth, 29.4% adjusted operating margins, and adjusted EPS of $1.37, $0.08 above the midpoint of its guidance.
• Life sciences organic growth reached 9%, led by high-single-digit reagent growth, mid-single-digit instrument growth, and upper-teens Signals Software growth. Management cited improving pharma and biotech demand, expanding AI-related activity, and growing instrument backlogs, particularly in high-content screening.
• The company raised its full-year outlook to approximately 5% pro forma organic growth and $5.40–$5.45 adjusted EPS, while increasing its operating-margin forecast to 28.8%. Efficiency initiatives and favorable mix are supporting more than 40% incremental margins.
• Diagnostics grew 5% organically, with margins reaching 29.9%; excluding the China immunodiagnostics business targeted for divestiture, margins exceeded 30%. Revvity also launched a type 1 diabetes screening assay in Europe, but reproductive health remains constrained by weak Chinese birth rates.
• Management expects some moderation in Q4 growth, partly because reagent bulk orders shifted into Q3 and Signals Software growth is expected to slow from the high teens to the mid-teens. AI demand is broadening but remains in its early stages, and the company expects no share repurchases in its Q4 guidance.

Revvity Stock Performance

NYSE:RVTY traded up $17.90 on Tuesday, reaching $169.50. 1,385,563 shares of the company’s stock were exchanged, compared to its average volume of 1,525,091. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The firm has a market cap of $18.91 billion, a price-to-earnings ratio of 80.55, a P/E/G ratio of 3.01 and a beta of 1.06. Revvity has a 52 week low of $81.22 and a 52 week high of $171.74. The stock has a fifty day simple moving average of $145.08 and a 200-day simple moving average of $112.36.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 12th. Shareholders of record on Friday, January 22nd will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 22nd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is 13.33%.

Analyst Ratings Changes

RVTY has been the topic of a number of research analyst reports. William Blair assumed coverage on shares of Revvity in a research note on Monday, October 5th. They issued an “outperform” rating on the stock. TD Cowen raised their price target on shares of Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. KeyCorp upped their price objective on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Finally, Barclays upped their price objective on Revvity from $115.00 to $160.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Five investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $124.43.

Insider Activity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tajinder Vohra sold 7,330 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 9,045 shares of company stock valued at $1,281,439 in the last quarter. Corporate insiders own 0.85% of the company’s stock.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.